Sara Silbert, MD, Gregory A. Yanik, MD, and Andrew G. Shuman, MD
“Living” drugs target specific B-cell malignancy tumor antigens, but cost hundreds of thousands of dollars. Value analysis can help determine whether to offer these customized drugs.
AMA J Ethics. 2019;21(10):E844-851. doi:
10.1001/amajethics.2019.844.
The DSM-5 Task Force’s handling of the ethical controversy over the bereavement exclusion demonstrates the need for more inclusive deliberative processes.
AMA J Ethics. 2017;19(2):192-198. doi:
10.1001/journalofethics.2017.19.2.pfor2-1702.
Michael Anderson, PhD and Susan Leigh Anderson, PhD
Two concerns (unknowability of how output is derived from input and overreliance on clinical decision support systems) are main sources of ethical questions about AI in health care.
AMA J Ethics. 2019;21(2):E125-130. doi:
10.1001/amajethics.2019.125.